Lorecivivint - Biosplice Therapeutics
Alternative Names: Adavivint - Biosplice Therapeutics; SM-04690Latest Information Update: 20 Jul 2024
At a glance
- Originator Samumed
- Developer Biosplice Therapeutics
- Class Amides; Anti-inflammatories; Antirheumatics; Fluorinated hydrocarbons; Imidazoles; Indazoles; Pyridines; Small molecules
- Mechanism of Action Clk dual-specificity kinase inhibitors; DYRK kinase inhibitors; Wnt signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Osteoarthritis
- Preclinical Intervertebral disc degeneration
Most Recent Events
- 12 Jul 2024 Updated efficacy and adverse events data from a phase III trial in Osteoarthritis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
- 12 Jun 2024 Pharmacodynamics data from a preclinical studies in Osteoarthritis presented at the 25th Annual Congress of the European League Against Rheumatism, 2024 (EULAR-2024)
- 12 Jun 2024 Updated efficacy data from the phase III STRIDES-X-ray trial in Osteoarthritis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)